Literature DB >> 11026701

The relationship between gastroesophageal reflux, intestinal metaplasia and adenocarcinoma of the esophagus.

H J Stein1, M Feith, H Feussner.   

Abstract

Currently available data indicate a clear and probably causal relationship between long-lasting gastroesophageal reflux disease, the development of long segments with specialized intestinal metaplasia in the distal esophagus and subsequent progression to adenocarcinoma. To a lesser degree, this also appears to be the case for short segments of specialized intestinal metaplasia in the distal esophagus. In contrast, epidemiological data and classic parameters for the diagnosis of gastroesophageal reflux disease do not currently support a causal role of gastroesophageal reflux in the pathogenesis of specialized intestinal metaplasia at the gastric cardia. Despite its high prevalence and malignant potential, many questions about the prevention and management of intestinal metaplasia in the distal esophagus remain unsolved. In patients with chronic gastroesophageal reflux, current modes of medical therapy do not appear to prevent the development of intestinal metaplasia, while effective anti-reflux surgery seems to have a protective effect. Formal studies with adequate follow-up are, however, still lacking. Neither acid-suppression therapy nor anti-reflux surgery, with or without mucosal ablation, can reliably prevent the malignant degeneration of established intestinal metaplasia of the esophagus. Close endoscopic surveillance with extensive biopsies, therefore, remains mandatory in such patients, irrespective of the treatment modality.

Entities:  

Mesh:

Year:  2000        PMID: 11026701     DOI: 10.1007/s004230000160

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  1 in total

Review 1.  Does anti-reflux surgery disrupt the pathway of Barrett's esophagus progression to cancer?

Authors:  Sebastian F Schoppmann; Ivan Kristo; Martin Riegler
Journal:  Transl Gastroenterol Hepatol       Date:  2018-12-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.